Business Context and Reporting Period
Company: Belite Bio, Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter 2026 (Unaudited)
Filing Date: August 12, 2026
Context: This filing incorporates by reference a press release announcing the company's unaudited financial results for the second quarter of 2026 and providing a corporate update.
Key Financial Metrics
The provided text is a cover sheet for Form 6-K and does not contain the specific financial data from the attached press release (Exhibit 99.1). Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific numerical comparisons or details regarding material changes versus the prior comparable period. It only references the existence of a press release containing this information.
Guidance, Outlook, and Risks
The filing indicates that a "Corporate Update" was issued alongside the financial results. However, the specific content regarding guidance, outlook, management commentary, risks, contingencies, or unusual items is not present in the provided text, as it is contained within the attached Exhibit 99.1.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release) for actual Q2 2026 financial figures, as they are not listed in the Form 6-K cover sheet.
- Verify the specific details of the "Corporate Update" mentioned in the press release title.
- Confirm the company's cash runway and liquidity position, which are critical for a biotech firm but are not detailed in this summary text.
- Check for any new risk factors or regulatory updates disclosed in the full press release.